A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

Study acronym: TITANS
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 1 → 6 locations
    • Eligibility criteria expanded, about 7 words
  2. Secondary endpoints revised (6)v2
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice
Trial Details
NCT Number NCT07652736
Lead Sponsor BeOne Medicines
Conditions
(from sponsor)		 Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer
Related terms Small Cell Lung Carcinoma
Enrollment 440 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov